PTCE Pharmacy Connect | Pharmacy Times

Caring for Patients With Multiple Myeloma Through Pharmacist-Directed Supportive Care and Toxicity Management Strategies | PTCE Pharmacy Connect

Introduction of faculty and disclosures: 
Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia.
Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi.
Accreditation and support statement: 
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis | PTCE Pharmacy Connect

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis
 
Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.
 
 
 
Melissa Pozotrigo, PharmD, BCOP
Senior Clinical Pharmacist
OncoHealth
Atlanta, Georgia
 
Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
 
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023.
This activity is supported by an educational grant from Incyte Corporation.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Achieving Treatment Goals in Myelofibrosis with JAK Inhibitors and Emerging Therapies | PTCE Pharmacy Connect

Educational Objective: Outline the standard treatment options for myelofibrosis as well as review clinical data for Janus kinase inhibitors and emerging targeted therapies.
 
 
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan
 
 
Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-396-H01-P. The activity is available for CE credit through August 29, 2023.
This activity is supported by an educational grant from Incyte Corporation.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Setting the Scene in Myelofibrosis Treatment and Management | PTCE Pharmacy Connect

Educational Objective: Review the etiology and pathophysiology of myelofibrosis, including the World Health Organization classification and diagnostic criteria.
 
 
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan
 
Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-381-H01-P. The activity is available for CE credit through August 29, 2023.
This activity is supported by an educational grant from Incyte Corporation.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Use of Novel Therapies in Endometrial Cancer: Update for Managed Care | PTCE Pharmacy Connect

Accreditation and support statement:
·   PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
·   This activity is supported by educational grant from GlaxoSmithKline.
Objectives
•   Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer.
•   Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.
 
Learn more about your ad choices. Visit megaphone.fm/adchoices

HIV Preexposure Prophylaxis (PrEP): Exploring the Current and Emerging Landscape | PTCE Pharmacy Connect

 Educational Objectives
·      Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV.
·      Describe the role of pharmacists in improving PrEP uptake in the United States. 
 
 
Faculty:
Drew W. Cates, PharmD, AAHIVP,
Educational Manager
SynerGrx
Chamblee, Georgia 
Faculty, has the following financial relationships with commercial interests to disclose:
Speaker's Bureau: Gilead
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.07 CEU) under the ACPE universal activity number 0290-0000-22-338-H02-P. The activity is available for CE credit through July 29, 2023.
This activity is supported by an educational grant from ViiV.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Multiple Myeloma: Pharmacists as Therapy Experts | PTCE Pharmacy Connect

Educational Objectives
Objective 1: Describe a strategy to mitigate potential adverse effects of MM therapies by altering the route of administration, dosing schedule, and use of supportive care medications
 
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Winship Cancer Institute, Emory Healthcare
Atlanta, Georgia
 
Kathryn Maples, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:  Consultant: GlaxoSmithKline, Janssen, Karyopharm, Sanofi
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity numbers 0290-0000-22-315-H01-P and 0290-0000-22-315-H01-T. The activity is available for CE credit through July 11, 2023.
 
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Examining the Treatment Landscape of Metastatic NSCLC Expressing the Targetable Mutations RET, MET, and KRAS | PTCE Pharmacy Connect

Educational Objectives
• Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC)
• Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations
 
Josiah D. Land, PharmD, BCOP
Clinical Pharmacy Specialist – Thoracic Medical Oncology
Department of Pharmacy
Memorial Sloan Kettering Cancer Center
New York, New York
 
Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant (advisory board): Bristol Myers Squibb
 
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.
 
This activity is supported by educational funding provided by Amgen.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Continuing the Conversation: Optimizing Frontline Immunotherapy Outcomes in NSCLC and Managed Care Considerations | PTCE Pharmacy Connect

Educational Objectives
·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens
·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC
 
Faculty:
Paul Forsberg, PharmD, MHA, BCOP
Director of Pharmacy
Minnesota Oncology
St. Paul, Minnesota
 
Latha Radhakrishnan, PharmD, BCOP
Clinical Oncology Pharmacist
The University of Illinois Hospital and Health Sciences System
Clinical Assistant Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
 
Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Epizyme
Speakers Bureau: AstraZeneca
 
Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Taiho, Novartis, Exelixis
Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis
 
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.
 
This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.
 https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations
Learn more about your ad choices. Visit megaphone.fm/adchoices

Caring for Patients With Multiple Myeloma Through Pharmacist-Directed Supportive Care and Toxicity Management Strategies | PTCE Pharmacy Connect

Introduction of faculty and disclosures: 
Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia.
Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi.
Accreditation and support statement: 
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
https://www.pharmacytimes.org/courses/multiple-myeloma-recognizing-treatment-options
Learn more about your ad choices. Visit megaphone.fm/adchoices